Introduction
Chronic hepatitis C virus (HCV) occurs in association with chronic inflammatory cell infiltration and hepatocellular necrosis because of HCV infection of the liver. Liver cirrhosis and the progression of hepatic fibrosis are critical stages of HCV-related liver disease, and can develop into hepatocellular carcinoma (HCC) in a multicentric manner. Therefore, the primary therapeutic goal of eradicating HCV by treatment with an antiviral drug is to terminate its progression to liver cirrhosis and HCC. 1, 2 Currently, the estimated number of patients with HCV is 71 million globally. 3 HCV is classified into six major genotypes (Gts), with Gt 1 being the most prevalent globally (49.1%), followed by Gt 3 (17.9%), 4 (16.8%), 2 (11.0%), and 5 or 6 (,5%). 4 Antiviral treatment for HCV infection has significantly improved since the advent of direct-acting antiviral (DAA) agents, such as boceprevir and telaprevir. First-generation DAAs with concomitant use of Pegylated interferon (IFN) and ribavirin (RBV) is associated with a high rate of adverse events (AEs). However, the combined use of second-generation DAAs without IFN, such as IFN-free regimens, improves treatment efficacy and decreases the incidence of AEs, yet a number of issues remain. As HCV patients get older, it becomes necessary to administer safer drugs. In addition, there are very limited treatment options for patients with chronic kidney disease (CKD), patients coinfected with HCV and HIV, patients with resistance-associated substitutions (RASs) as a result of prior treatment including DAAs, and patients with coadministered drugs due to complicated diseases. As such, novel agents with enhanced efficacy, tolerability, and convenience are required for unmet medical needs.
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Recently, combination treatment with both the HCV nonstructural (NS) protein 5A inhibitor elbasvir (EBR; Figure 1A ) 5 and the HCV NS3/4A protease inhibitor grazoprevir (GZR; Figure 1B ) 6 was approved in many countries for the treatment of patients with chronic HCV and Gt 1 and 4. This review covers the mode of action, pharmacokinetics, clinical applications, efficacy, and safety profile of EBR/ GZR, including special populations, from evidence to date.
Properties of elbasvir/grazoprevir
EBR inhibits HCV NS5A, which is necessary for assembly of the viral replication complex, RNA synthesis, and virion assembly ( Figure 2 ). [7] [8] [9] [10] EBR has median effective concentration (EC 50 ) values against chimeric replicons containing NS5A from clinical isolates of Gt 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6 of 4, 3, 3, 3,400, 140, 0.3, 1, and 9 pM, respectively (Table 1) . 11 GZR inhibits HCV NS3/4A protease, which has serine protease and NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication, and assembly ( Figure 2) . [12] [13] [14] GZR has median EC 50 values against chimeric replicons containing NS3/4A from clinical isolates of Gt 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6 of 400, 500, 2,300, 3,700, 35,000, 300, 6,600, and 200 pM, respectively (Table 2) . 11 In the HCV-replicon assay, the antiviral activity of EBR is reduced one-to 929-fold by single NS5A substitutions (known as RASs) at amino-acid positions M28T/V/A, Q30D/H/E/R, L31M/V/F, H58D, and Y93H/N/C in the HCV Gt 1a replicon, one-to 17-fold by single NS5A substitutions at amino-acid positions L28M, L31M/F/V, Y93H, and V121I in the HCV Gt 1b replicon, and one-to 7.5-fold by single NS5A substitutions at amino-acid positions L30F/P/S, M31V, N69K, and Y93H in the HCV Gt four replicon (Table 3) . 11, 15, 16 In the same way, the antiviral activity of GZR is reduced 1.1-to 114-fold by single NS3 substitutions at amino-acid positions V36A, T54S, Y56H, Q80K, R155K, A156S, and D168A/Y/T in the HCV Gt 1a replicon, 0.6-to 262-fold by single NS3 substitutions at amino-acid positions Q41R, F43S, R155K, A156T, and D168Y in the HCV genotype 1b replicon, and 47.1-to 137.1-fold by double-NS3 substitutions at amino-acid positions G162R with D168A, and G162R with D168V in the HCV Gt 4 replicon (Table 4) . 11, 15, 16 Concentrations of 50 mg EBR and 100 mg GZR can be administered as a fixed-dose combination of a single oncedaily tablet. Peak plasma concentrations of EBR and GZR are reached at a median of 3 and 2 hours, respectively, after oral administration, 5, 6 and steady-state pharmacokinetics reached within 6 days. EBR/GZR can be administered without regard to food, as changes in drug exposure are not clinically relevant after a high-calorie, high-fat meal in healthy subjects. EBR and GZR are highly bound to 99.9% and 98.8% of plasma proteins, respectively. Both EBR and GZR are mainly metabolized by CYP3A, after which both agents are predominantly excreted in feces. The approximate half-lives of EBR and GZR are 24 and 31 hours, respectively. EBR/GZR dose does not need to be adjusted in patients with renal impairment, including those on hemodialysis. Both EBR and GZR are CYP3A substrates, and thus coadministration of EBR/GZR with strong CYP3A inducers is contraindicated. GZR is a substrate of organic anion-transporting polypeptides 1B1/3 (OATP1B1/3), and thus coadministration of EBR/GZR with OATP1B1/3 inhibitors is also contraindicated. Plasma concentrations of tacrolimus and statins have the potential to increase after combination use of EBR/GZR, so clinical monitoring after administration of those drugs is recommended. However, EBR/GZR does not have any specific prohibition and caution as concomitant medications relative to the same class of drugs. It is not necessary either to take special consideration in combination use of EBR/GZR with calcium blockers, proton-pump inhibitors, or oral contraceptive drugs.
Clinical outcomes of elbasvirgrazoprevir
In the C-EDGE TN trial, in treatment-naïve (TN) patients infected with Gt 1a or 1b and receiving EBR/GZR for 12 weeks 
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EBR/GZR treatment for HCV without RBV, sustained virological response at 12 weeks (SVR12) was 92% in patients infected with Gt 1a and 99% in those infected with Gt 1b (Table 5) . 17 The presence of compensated cirrhosis in 23% of patients had no effect on SVR12.
In the open-label C-EDGE COINFECTION trial, TN patients coinfected with HIV with or without compensated cirrhosis were treated with EBR/GZR for 12 weeks. SVR12 rates were 97% in patients infected with Gt 1a and 95% in those infected a Names and numbers are strain designations and GenBank accession numbers; b JFH1-based chimeric replicon harboring NS5A sequences of Gt 2b, 5a, and 6 were used. values are mean ± SD (n$3). Adapted with permission from Lahser FC, Bystol K, Curry S, et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother. 2016;60(5):2954-2964.
11
Abbreviations: eC, effective concentration; HCv, hepatitis C virus. 18 In DAA-naïve HCV Gt 1a-infected patients who received a 12-week regimen of EBR/GZR, the presence of baseline NS5A polymorphisms at amino-acid positions M28, Q30, L31, and Y93 was associated with reduced efficacy.
Patients with NS5A polymorphisms at amino-acid positions Q30H/L/R or L31M had particularly low SVR12 rates (,50%). 19 In HCV Gt 1b-infected patients who received a 12-week regimen of EBR/GZR, the presence of baseline NS5A polymorphisms was associated with slightly reduced SVR12 rates. 19, 20 Moreover, in HCV Gt 4-infected patients who received a 12-week regimen of EBR/GZR, the presence of baseline NS5A polymorphisms had little influence on SVR12 rates. 19 Despite the fact that baseline NS3 RASs were commonly observed, a 12-week regimen of EBR/GZR demonstrated high SVR12 rates among patients infected with Gt 1a, 1b, or 4. 17, [19] [20] [21] [22] [23] [24] In treatment-experienced (TE) patients in the C-EDGE TE Phase III trial, including 34% of patients with compensated cirrhosis, SVR12 rates in patients infected with Gt 1a and 1b were 92% and 100%, respectively, after 12 weeks of EBR/GZR without RBV, 93% and 97%, respectively, after 12 weeks with RBV, 94% and 98%, respectively, after 16 weeks without RBV, and 100% and 100%, respectively, after 16 weeks with RBV. 24 Treatmentemergent NS5A substitutions were observed at amino-acid positions M28A/G/T, Q30H/K/R/Y, L31F/M/V, H58D, and Y93H/N/S in HCV Gt 1a, L28M, L31F/V, and Y93H in HCV Gt 1b, and L28S/T, M31I/V, P58D and Y93H in HCV Gt 4. Treatment-emergent NS3 substitutions were also observed at amino-acid positions V36L/M, Y56H, V107I, R155I/K, A156G/T/V, V158A, and D168A/G/N/V/Y in HCV Gt 1a, Y56F, V107I and A156T in HCV Gt 1b, and A156M/T/V, D168A/G, and V170I in HCV Gt 4 among patients receiving EBR/GZR with and without RBV and who experienced virologic failure in Phase II or III clinical trials. 19 The safety of EBR/GZR has been based on Phase II and III clinical studies, and the most commonly reported AEs are fatigue and headache. Rare cases (0.8%) of substantial elevations in alanine aminotransferase levels have been reported. Less than 1% of subjects treated with EBR/GZR with or without RBV discontinued treatment due to AEs. 
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EBR/GZR treatment for HCV
Advanced CKD
The prevalence of HCV in patients with CKD is higher than that in the general population, with an incidence of 5%-10% in Europe and the USA. 25, 26 The prevalence of HCV is also closely associated with the length of time on hemodialysis. 27 Moreover, dialysis patients with HCV have a higher mortality rate than those without HCV. 28 In the long term, the treatment of HCV-infected patients with CKD is limited by low efficacy and high AEs with IFN and RBV treatment. 29 The development of DAAs has dramatically changed the prognosis for patients with HCV receiving dialysis. Until recently, all clinical trials excluded patients with CKD stage 4-5, due to a lack of safety data in patients with advanced CKD. However, this situation changed with the contribution of the C-SURFER study, 30 which was the first randomized trial to include patients with CKD stage 4 to evaluate the efficacy and safety of EBR/GZR for HCV treatment. 30 In this trial, 224 patients, 76% of whom were hemodialysis patients, were enrolled. This study included equal proportions of patients infected with HCV Gt 1a and 1b. SVR12 was achieved in 94% of patients. Six patients discontinued treatment for reasons other than virologic failure, and one noncirrhotic patient with HCV Gt 1b and NS5A-L31M RASs experienced a virological relapse. AEs were observed in 15.6% of patients and were generally mild. The most frequent AEs were headache, nausea, and fatigue. Serious AEs did not lead to drug discontinuation. There was no significant renal or hepatic impairment. The well-tolerated oral regimens for HCV have expanded the treatment strategies available for patients with CKD stage 4-5 and hemodialysis.
HIV coinfection
The overall global prevalence of HIV-HCV coinfection is about 6.2%. 31 HIV accelerates liver fibrosis in patients coinfected with HCV through several different mechanisms, 32 and treatment for chronic HCV infection is urgently needed in this patient population. Sulkowski et al 33 reported Phase II results of the C-WORTHY trial, which evaluated the efficacy of 8 or 12 weeks of EBR/GZR with or without RBV in HCV Gt 1 monoinfected and HIV-HCV coinfected patients. Rockstroh et al 18 also reported Phase III results of the C-EDGE COINFECTION trial, which tested the efficacy of 12 weeks of EBR/GZR without RBV in patients with HIV and HCV Gt 1, 4, or 6 coinfection. This EBR/GZR regimen can be used in combination with HIV-integrase inhibitors and a number of nucleoside reverse-transcriptase inhibitors without any dosage adjustment. Both clinical trials showed high SVR rates and a good safety profile for EBR/GZR regimens.
Compensated cirrhosis
Rockstroh et al 18 reported the effects of EBR/GZR in patients with HCV infection and compensated cirrhosis, combining data from six clinical trials (C-SURFER, 30 C-EDGE COINFECTION, C-EDGE TN, 17 and C-EDGE TE 24 [Phase III], and C-WORTHY 33 and C-SALVAGE 22 [Phase II]). The authors performed integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in six clinical trials. All patients received EBR/GZR with or without RBV for 12-18 weeks. Among TN and TE patients receiving EBR/GZR for 12 weeks, 97.8% and 88.9% achieved SVR12, respectively. Among patients receiving EBR/GZR for 12 weeks with RBV, the SVR12 rate did not increase in TN or TE patients. TE patients receiving EBR/GZR with or without RBV for 16 or 18 weeks achieved SVR12 of 100% and 93.9%, respectively. Virologic failure was observed more frequently in Gt 1a-infected patients than in patients infected with Gt 1b or 4. HCV Gt 1a-infected patients with baseline RASs in NS5A receiving EBR/GZR for 12 weeks achieved SVR12 of 73%. Serious AEs were reported in 3% of patients, and no patient had a hepatic failure-related event. a Low HCV RNA defined as #800,000 (5.9 log) IU/mL; b high HCV RNA defined as .800,000 (5.9 log) IU/mL. Abbreviations: AASLD, American Association for the Study of Liver Disease; eASL, european Association for the Study of the Liver; Gt, genotype; HCv, hepatitis C virus; IDSA, Infectious Diseases Society of America; PI, protease inhibitor; P/R, PEGylated interferon and ribavirin; RASs, resistance-associated substitutions; RBV, ribavirin; TE, treatment-experienced; TN, treatment-naïve.
Decompensated cirrhosis
Pharmacokinetic data from hepatic-impairment studies in non-HCV-infected subjects have demonstrated a decrease in EBR area under the curve in Child-Pugh A (39%), ChildPugh B (28%), and Child-Pugh C (12%). 34 In contrast, GZR exposure is increased in Child-Pugh A (double), Child-Pugh B (fivefold), and Child-Pugh C (12-fold). 35 EBR/GZR use is contraindicated in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) liver cirrhosis, as they may have significantly increased GZR exposure that might lead to an increased risk of elevated transaminase levels.
Pangenotypic use
The Phase II C-SCAPE study evaluated EBR/GZR with or without RBV in participants with HCV genotype 2, 4, 5, or 6 infection. 36 Among participants with Gt 2 infection, SVR12 was achieved by 80% (24 of 30) of those receiving EBR/ GZR + RBV. The addition of RBV to EBR/GZR appeared to increase SVR12 rates in participants with Gt 5 infection from 25% (one of four) to 100% (four of four). These results indicated that EBR/GZR ± RBV was unsatisfactory in patients with HCV Gt 2 or 5 infection. SVR12 rates for HCV Gt 4 and 6 were similar to those found in other studies.
Conclusion
The ultimate goal of HCV therapy is not only to eradicate HCV infection but also to prevent HCV-related deaths, including liver-related disease, HCC, and extrahepatic complications. Current recommendations from the American Association for the Study of Liver Disease, European Association for the Study of the Liver, and Infectious Diseases Society of America guidelines on EBR/GZR are shown in Table 6 . Limitations of EBR/ GZR are the occurrence of potential concomitant drug-drug interactions, the absence of pangenotypic efficacy, the need for baseline evaluation of RASs in Gt 1a-infected patients, and the putative hepatotoxicity of protease inhibitors in Child-Pugh B and C cirrhosis in a minority of clinical situations. However, the fixed-dose once-daily oral combination regimen of EBR/ GZR has beneficial effects in antiviral treatment for HCV Gt 1-and 4-infected TN and TE patients, with or without compensated cirrhosis, HIV coinfection, or advanced CKD.
Abbreviations
AASLD, American Association for the Study of Liver Disease; AE, adverse event; CKD, chronic kidney disease; DAA, directacting antiviral; EASL, European Association for the Study of the Liver; EBR, elbasvir; Gt, genotype; GZR, grazoprevir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IDSA, Infectious Diseases Society of America; LC, liver cirrhosis; NS, nonstructural; RAS, resistance-associated substitution; RBV, ribavirin; SVR12, sustained virological response at 12 weeks; TE, treatment-experienced; TN, treatment-naïve.
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